Coherus Oncology, Inc. (CHRS)

Biological Products, (No Diagnostic Substances)

Latest Price

$1.41

TTM P/E

0.86

Normalized P/E

Div Yield

Book Value

0.58

P/B Ratio

2.45

Valuation metrics

EPS: $1.43

Book value / share: $0.50

Formula: √(22.5 × EPS × BVPS)

Graham Number

$4.03

+185% upside

Base FCF: $87M (median of recent 5yr)

Growth: 25%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$54.69

+3779% upside

EPS: $1.43

Target P/E: 1×

Formula: EPS × P/E

P/E Fair Value

$1.43

+1% upside

36.4% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	10.37M	$17.0M	6.72%	-197.6K	2026-03-31
VANGUARD CAPITAL MANAGEMENT LLC	5.45M	$9.0M	3.54%	--	2026-03-31
SAMSARA BIOCAPITAL, LLC	3.43M	$5.0M	2.22%	--	2026-03-31
GEODE CAPITAL MANAGEMENT, LLC	3.12M	$5.0M	2.02%	+376.3K	2026-03-31
Kohlberg Kravis Roberts & Co. L.P.	3.04M	$5.0M	1.97%	--	2026-03-31
STATE STREET CORP	2.33M	$3.0M	1.51%	+102.5K	2026-03-31
Alyeska Investment Group, L.P.	2.25M	$3.0M	1.46%	--	2026-03-31
CM Management, LLC	2.10M	$3.0M	1.36%	--	2026-03-31
C WorldWide Group Holding A/S	1.93M	$3.0M	1.25%	--	2026-03-31
TANG CAPITAL MANAGEMENT LLC	1.89M	$3.0M	1.22%	-837.8K	2026-03-31